47 citations,
June 2017 in “Journal of dermatology” New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.
44 citations,
April 2019 in “Journal of the American Academy of Dermatology” Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
43 citations,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
42 citations,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
29 citations,
June 2013 in “Journal of the Saudi Society of Dermatology & Dermatologic Surgery” Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
25 citations,
December 2015 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
22 citations,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
20 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.
19 citations,
January 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
17 citations,
April 2020 in “Dermatology and Therapy” The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
17 citations,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
12 citations,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
12 citations,
September 2020 in “Journal of cosmetic dermatology” Trichoscopy is useful for diagnosing and monitoring alopecia areata treatment.
12 citations,
June 2017 in “Dermatologic therapy” Higher concentrations of dithranol can help regrow hair in severe alopecia areata.
12 citations,
January 2011 in “Photodermatology, photoimmunology & photomedicine” This therapy effectively treats resistant alopecia areata with minimal side effects.
11 citations,
May 2021 in “Journal of The American Academy of Dermatology” COVID-19 doesn't make alopecia areata worse.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
11 citations,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
10 citations,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
9 citations,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
9 citations,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
9 citations,
January 2019 in “International Journal of Trichology” Combining calcipotriol with mometasone is more effective for treating alopecia areata than using mometasone alone.
6 citations,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
6 citations,
February 2021 in “Advances in Clinical and Experimental Medicine” Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.
5 citations,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
4 citations,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
4 citations,
January 2020 in “International Journal of Trichology” Too much epidermal growth factor can cause hair loss.
3 citations,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.